<p>Voyager Therapeutics（納斯達克：VYGR - 獲取免費報告）於週一發佈了季度財報。該公司報告季度每股收益為（$0.47），超出分析師一致預期的（$0.53）$0.06，Zacks 報道。Voyager Therapeutics 的股本回報率為負 37.65%，淨利潤率為負 253.49%。</p>
<p>獲取 <strong>Voyager Therapeutics</strong> 的提醒：</p>
<h2>Voyager Therapeutics 股票表現</h2>
<ul>
<li>Voyager Therapeutics 股票因與諾華達成交易上漲 30%</li>
</ul>
<p>週一中午交易時，納斯達克 VYGR 上漲 $0.03，達到 $4.26。該股票交易量為 556,597 股，低於其 573,133 的平均交易量。該公司的 50 日簡單移動平均為$4.51，200 日簡單移動平均為$3.71。Voyager Therapeutics 的 1 年最低價為$2.64，最高價為$7.44。該股票的市值為 2.363 億美元，市盈率為-2.30，貝塔值為 0.95。</p>
<h2>內部買賣</h2>
<p>在相關消息中，首席財務官 Nathan D. Jorgensen 於 10 月 3 日星期五出售了 7,666 股公司的股票。該股票以平均價格$4.78 出售，總交易額為$36,643.48。交易後，首席財務官直接持有 123,834 股公司股票，價值約$591,926.52。此次交易使其持股減少了 5.83%。該交易已在向 SEC 的法律文件中披露，SEC 網站上可以訪問。4.53% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些大型投資者最近調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第三季度將其在 Voyager Therapeutics 的持股提高了 1.3%。先鋒集團目前持有 3,250,066 股公司股票，價值$15,178,000，在此期間又購買了 40,147 股。Geode Capital Management LLC 在第二季度將其在 Voyager Therapeutics 的持股提高了 1.1%。Geode Capital Management LLC 目前持有 1,116,847 股公司股票，價值$3,474,000，在上個季度又收購了 11,929 股。AQR Capital Management LLC 在第一季度將其在 Voyager Therapeutics 的持股提高了 179.3%。AQR Capital Management LLC 目前持有 495,260 股公司股票，價值$1,674,000，在上個季度又購買了 317,927 股。Acadian Asset Management LLC 在第一季度將其在 Voyager Therapeutics 的持股提高了 863.3%。Acadian Asset Management LLC 目前持有 230,708 股公司股票，價值$778,000，在此期間又購買了 206,758 股。最後，滙豐控股（Hsbc Holdings PLC）在第二季度將其在 Voyager Therapeutics 的持股提高了 118.5%。滙豐控股目前持有 148,377 股公司股票，價值$440,000，在上個季度又收購了 80,474 股。目前 48.03% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師觀點</h2>
<p>VYGR 最近成為幾份研究報告的主題。Wedbush 在 8 月 7 日的研究報告中將 Voyager Therapeutics 的目標股價從$9.00 下調至$8.00，並對該股票給予 “跑贏大盤” 的評級。HC Wainwright 在 9 月 15 日的報告中重申了 “買入” 評級，並將 Voyager Therapeutics 的目標股價設定為$30.00。最後，Weiss Ratings 在 10 月 8 日的研究筆記中重申了對 Voyager Therapeutics 的 “賣出（d）” 評級。六位股票研究分析師對該股票給予了買入評級，一位分析師對公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標股價為$12.96。</p>
<p><strong>閲讀我們對 VYGR 的最新分析</strong></p>
<h2>Voyager Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Voyager Therapeutics, Inc.是一家生物技術公司，專注於基因治療和神經疾病的治療。該公司的主要臨牀候選藥物是 VY-TAU01，一種針對阿爾茨海默病的抗 tau 抗體項目。其產品管線包括超氧化物歧化酶 1 沉默基因治療，正在進行肌萎縮側索硬化症的臨牀前試驗；tau 沉默基因治療，正在進行阿爾茨海默病的臨牀前試驗；以及針對阿爾茨海默病的抗澱粉樣蛋白基因治療，正在進行臨牀前試驗。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Voyager Therapeutics</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>Monday.com 因瘋狂拋售開啓了代際機會</li>
<li>如何計算期權利潤</li>
<li>股票下跌中的盈利勝利：D-Wave 發生了什麼？</li>
<li>投資者需要知道的以擊敗市場的信息</li>
<li>3 只在市場回調時顯示相對強勢的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Voyager Therapeutics 嗎？</h2>
<p>在考慮投資 Voyager Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Voyager Therapeutics 並不在名單上。</p>
<p>雖然 Voyager Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看五隻股票</p>

VYGR

<p>Voyager Therapeutics（納斯達克代碼：VYGR）報告每股收益為（$0.47），超出預期的（$0.53）$0.06。該公司的股本回報率為負 37.65%，淨利潤率為負 253.49%。在財報發佈後，Voyager 的股票上漲了 30%，達到$4.26。機構投資者持有該公司 48.03% 的股份，主要公司近期對持股進行了調整。分析師的評級不一，平均目標價為$12.96，顯示出 “適度買入” 的情緒</p>

<p>Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.06, Zacks reports. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.</p>
<div class="lb-trans"><p>Voyager Therapeutics（納斯達克：VYGR - 獲取免費報告）於週一發佈了季度財報。該公司報告季度每股收益為（$0.47），超出分析師一致預期的（$0.53）$0.06，Zacks 報道。Voyager Therapeutics 的股本回報率為負 37.65%，淨利潤率為負 253.49%。</p>
</div><p>Get <strong>Voyager Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Voyager Therapeutics</strong> 的提醒：</p>
</div><h2>Voyager Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Voyager Therapeutics 股票表現</h2>
</div><ul>
<li>Voyager Therapeutics stock pops 30% on deal with Novartis</li>
</ul>
<div class="lb-trans"><ul>
<li>Voyager Therapeutics 股票因與諾華達成交易上漲 30%</li>
</ul>
</div><p>NASDAQ VYGR traded up $0.03 during mid-day trading on Monday, reaching $4.26. 556,597 shares of the stock were exchanged, compared to its average volume of 573,133. The business's fifty day simple moving average is $4.51 and its 200 day simple moving average is $3.71. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $7.44. The stock has a market capitalization of $236.30 million, a PE ratio of -2.30 and a beta of 0.95.</p>
<div class="lb-trans"><p>週一中午交易時，納斯達克 VYGR 上漲 $0.03，達到 $4.26。該股票交易量為 556,597 股，低於其 573,133 的平均交易量。該公司的 50 日簡單移動平均為$4.51，200 日簡單移動平均為$3.71。Voyager Therapeutics 的 1 年最低價為$2.64，最高價為$7.44。該股票的市值為 2.363 億美元，市盈率為-2.30，貝塔值為 0.95。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the business's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the transaction, the chief financial officer directly owned 123,834 shares of the company's stock, valued at approximately $591,926.52. The trade was a 5.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.53% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席財務官 Nathan D. Jorgensen 於 10 月 3 日星期五出售了 7,666 股公司的股票。該股票以平均價格$4.78 出售，總交易額為$36,643.48。交易後，首席財務官直接持有 123,834 股公司股票，價值約$591,926.52。此次交易使其持股減少了 5.83%。該交易已在向 SEC 的法律文件中披露，SEC 網站上可以訪問。4.53% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Voyager Therapeutics by 1.3% during the third quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company's stock worth $15,178,000 after purchasing an additional 40,147 shares during the period. Geode Capital Management LLC increased its position in shares of Voyager Therapeutics by 1.1% during the second quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company's stock valued at $3,474,000 after acquiring an additional 11,929 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock worth $1,674,000 after buying an additional 317,927 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock worth $778,000 after purchasing an additional 206,758 shares during the period. Finally, Hsbc Holdings PLC increased its holdings in Voyager Therapeutics by 118.5% in the 2nd quarter. Hsbc Holdings PLC now owns 148,377 shares of the company's stock worth $440,000 after acquiring an additional 80,474 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第三季度將其在 Voyager Therapeutics 的持股提高了 1.3%。先鋒集團目前持有 3,250,066 股公司股票，價值$15,178,000，在此期間又購買了 40,147 股。Geode Capital Management LLC 在第二季度將其在 Voyager Therapeutics 的持股提高了 1.1%。Geode Capital Management LLC 目前持有 1,116,847 股公司股票，價值$3,474,000，在上個季度又收購了 11,929 股。AQR Capital Management LLC 在第一季度將其在 Voyager Therapeutics 的持股提高了 179.3%。AQR Capital Management LLC 目前持有 495,260 股公司股票，價值$1,674,000，在上個季度又購買了 317,927 股。Acadian Asset Management LLC 在第一季度將其在 Voyager Therapeutics 的持股提高了 863.3%。Acadian Asset Management LLC 目前持有 230,708 股公司股票，價值$778,000，在此期間又購買了 206,758 股。最後，滙豐控股（Hsbc Holdings PLC）在第二季度將其在 Voyager Therapeutics 的持股提高了 118.5%。滙豐控股目前持有 148,377 股公司股票，價值$440,000，在上個季度又收購了 80,474 股。目前 48.03% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>VYGR has been the topic of several recent research reports. Wedbush lowered their price target on shares of Voyager Therapeutics from $9.00 to $8.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 7th. HC Wainwright restated a &#34;buy&#34; rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th. Finally, Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $12.96.</p>
<div class="lb-trans"><p>VYGR 最近成為幾份研究報告的主題。Wedbush 在 8 月 7 日的研究報告中將 Voyager Therapeutics 的目標股價從$9.00 下調至$8.00，並對該股票給予 “跑贏大盤” 的評級。HC Wainwright 在 9 月 15 日的報告中重申了 “買入” 評級，並將 Voyager Therapeutics 的目標股價設定為$30.00。最後，Weiss Ratings 在 10 月 8 日的研究筆記中重申了對 Voyager Therapeutics 的 “賣出（d）” 評級。六位股票研究分析師對該股票給予了買入評級，一位分析師對公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “適度買入”，平均目標股價為$12.96。</p>
</div><p><strong>Read Our Latest Analysis on VYGR</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 VYGR 的最新分析</strong></p>
</div><h2>Voyager Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Voyager Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.</p>
<div class="lb-trans"><p>Voyager Therapeutics, Inc.是一家生物技術公司，專注於基因治療和神經疾病的治療。該公司的主要臨牀候選藥物是 VY-TAU01，一種針對阿爾茨海默病的抗 tau 抗體項目。其產品管線包括超氧化物歧化酶 1 沉默基因治療，正在進行肌萎縮側索硬化症的臨牀前試驗；tau 沉默基因治療，正在進行阿爾茨海默病的臨牀前試驗；以及針對阿爾茨海默病的抗澱粉樣蛋白基因治療，正在進行臨牀前試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Voyager Therapeutics</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Monday.com Opens Generational Opportunity With Manic Sell-Off</li>
<li>How to Calculate Options Profits</li>
<li>An Earnings Win With a Stock Slump: What's Happening With D-Wave?</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>3 Stocks Showing Relative Strength as Markets Pull Back</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Voyager Therapeutics</li>
<li>突破股票：它們是什麼以及如何識別它們</li>
<li>Monday.com 因瘋狂拋售開啓了代際機會</li>
<li>如何計算期權利潤</li>
<li>股票下跌中的盈利勝利：D-Wave 發生了什麼？</li>
<li>投資者需要知道的以擊敗市場的信息</li>
<li>3 只在市場回調時顯示相對強勢的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VllHUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=VYGR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Voyager Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Voyager Therapeutics 嗎？</h2>
</div><p>Before you consider Voyager Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Voyager Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Voyager Therapeutics 並不在名單上。</p>
</div><p>While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Voyager Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看五隻股票</p>
</div>

Voyager Therapeutics (NASDAQ:VYGR) 公佈了收益結果，每股收益比預期高出 0.06 美元